Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 11:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,202 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pairing condition Clear all
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

NCT02961218
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
8 Years to 20 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Atlanta, Georgia • Augusta, Georgia • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 8, 2026, 11:03 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

NCT02059291
View directory record Official record
Conditions
Hereditary Periodic Fevers
Interventions
Canakinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Sep 8, 2026, 11:03 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Effects of Multiple Concussions in Retired NHL Players

NCT02746523
View directory record Official record
Conditions
Cognitive Deficits, Proprioceptive Disorders
Interventions
Sensory Organization Test, Biomarkers, Conners' Adult ADHD Rating Scale (CAARS), Depression Scale, Cognitive Assessment
Other · Genetic
Lead sponsor
New York Institute of Technology
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Old Westbury, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Sep 8, 2026, 11:03 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

NCT06400225
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Radionuclide Imaging, Ulixertinib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 8, 2026, 11:03 AM EDT
Completed Phase 3 Interventional Results available

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

NCT03112174
View directory record Official record
Conditions
Mantle-Cell Lymphoma
Interventions
Ibrutinib, Venetoclax, Placebo Oral tablet to match Venetoclax
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
14
States / cities
Tucson, Arizona • Duarte, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Sep 8, 2026, 11:03 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07179380
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Treprostinil Palmitil Inhalation Powder, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Los Angeles, California • Santa Barbara, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 8, 2026, 11:03 AM EDT
Completed Phase 4 Interventional Results available

Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.

NCT01148979
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lisdexamfetamine Dimesylate (Vyvanse), Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Sep 8, 2026, 11:03 AM EDT
Recruiting Phase 2Phase 3 Interventional

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

NCT05312879
View directory record Official record
Conditions
Proteinuric Kidney Disease
Interventions
VX-147, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
10 Years to 65 Years
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
227
States / cities
Alabaster, Alabama • Birmingham, Alabama • Fairhope, Alabama + 145 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 8, 2026, 11:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants

NCT06502379
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD8965, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 8, 2026, 11:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Chokeberry to Reduce Cardiovascular Disease Risk in Former Smokers

NCT01541826
View directory record Official record
Conditions
Cardiovascular Disease, Oxidative Stress
Interventions
Chokeberry Extract, Placebo capsule, Chokeberry extract capsule, acute
Dietary Supplement
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 8, 2026, 11:03 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias

NCT00061568
View directory record Official record
Conditions
Congenital Hemolytic Anemia, Sickle Cell Disease
Interventions
Peripheral blood hematopoietic progenitor cell (PBPC) transplant, Alemtuzumab, Peripheral blood hematopoietic progenitor cell Apheresis, Sirolimus
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Sep 8, 2026, 11:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

OSA in Pregnant Women With Chronic HTN

NCT03230110
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Pregnancy, Hypertension
Interventions
WP200U home sleep study device
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Sep 8, 2026, 11:03 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease

NCT06986382
View directory record Official record
Conditions
Crohn Disease
Interventions
CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Prednisone/Methylprenisolone, Palifermin, ATG, Clofarabine, Melphalan, Total Body Irradiation, Rituximab
Device · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 30 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 8, 2026, 11:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Extracellular Signal-Related Kinase Biomarker Development in Autism

NCT01850459
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 25 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Sep 8, 2026, 11:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics

NCT05478278
View directory record Official record
Conditions
QTc Interval, Pharmacokinetics
Interventions
Psilocybin, Moxifloxacin, Micro-Crystalline Cellulose
Drug
Lead sponsor
Usona Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Sep 8, 2026, 11:03 AM EDT
Terminated Phase 2 Interventional Results available

Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease

NCT04795466
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Canakinumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 90 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Charlestown, Massachusetts • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 8, 2026, 11:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults

NCT01962961
View directory record Official record
Conditions
HIV, Endothelial Dysfunction, Oxidative Stress
Interventions
PharmaNAC (N-acetylcysteine), Matching placebo
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 8, 2026, 11:03 AM EDT
Completed Phase 3 Interventional Results available

KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD

NCT02268994
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
ferric citrate, Placebo
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
36
States / cities
Phoenix, Arizona • Tempe, Arizona • Glendale, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Sep 8, 2026, 11:03 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis

NCT02494479
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Prurisol, Placebo
Drug
Lead sponsor
Cellceutix Corporation
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Huntsville, Alabama • Encino, California • Coral Gables, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Sep 8, 2026, 11:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)

NCT01528241
View directory record Official record
Conditions
Depression
Interventions
ABP688
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
55 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
New York, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 8, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder

NCT05113953
View directory record Official record
Conditions
Binge-Eating Disorder
Interventions
Centanafadine, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
25
States / cities
Phoenix, Arizona • Beverly Hills, California • Encino, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 8, 2026, 11:03 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder

NCT03352453
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Birmingham, Alabama • Garden Grove, California • Glendale, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Sep 8, 2026, 11:03 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Auditory EEG and Behavioral Assessments in Individuals With Rett Syndrome

NCT07569445
View directory record Official record
Conditions
Rett Syndrome
Interventions
Electroencephalogram (EEG) Recording
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
2 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 8, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus

NCT05593432
View directory record Official record
Conditions
Cutaneous Lichen Planus
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 8, 2026, 11:03 AM EDT